AstraZeneca Acquires Omniose; Financial Terms Not Disclosed

Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.

Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilities and supporting its preclinical vaccine programs.